Skip to main content

Table 2 Tumor characteristics

From: Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study

  Data Numbers (%)
Tumor histology
(n = 107)
Neuroblastoma 99 (92.5)
Ganglioneuroblastoma, intermixed 8 (7.5)
Tumor differentiation
(n = 73)
Undifferentiated 30 (41.2)
Poorly differentiated 35 (47.9)
Differentiated 8 (10.9)
MYCN amplification
(n = 51)
MYCN non-amplified 39 (76.4)
MYCN amplified 12 (23.5)
Shimada histology
(n = 32)
Unfavorable 23 (71.9)
Favorable 9 (28.1)
  1. Notes: Data are presented as number (%) for categorical variables
\